Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(33%)
Results Posted
50%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
1
17%
Ph phase_2
4
67%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Recruiting2
Terminated2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

recruiting233%
terminated233%
completed233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_3

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

NCT06618664
recruitingphase_1

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

NCT06157827
completedphase_2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

NCT05665348
terminatedphase_2

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

NCT05180006
terminatedphase_2

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

NCT05776875
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06618664Phase 3

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
NCT06157827Phase 1

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting
NCT05665348Phase 2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Completed
NCT05180006Phase 2

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Terminated
NCT05776875Phase 2

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Terminated
NCT05007613Phase 2

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6